Mint it
Looking over the results released by Beta Bionics yesterday what stood out most was their update on their MINT patch pump program. The company expects to fully commercialize the MINT at the end of the 2nd quarter of 2027. This would be about the same time when MiniMed launches their FIT patch pump and Tandem launches the tubeless version of the Mobi or what we call the Tobi. ViCentra the...
Where AI might help
Think I found an area where AI can have an immediate benefit. As I have noted in previous posts the one thing AI is very good at is crunching data. AI can gather data quickly and then present its findings back to the user. So how about developing an AI application helping someone chose an insulin pump platform. Something that used to be easy but thanks to the plethora of...
The BIG question
There is no doubt that AI is going to play an increasing role in diabetes management. Just yesterday OpenAI made its Health in ChatGPT feature broadly available, enabling U.S. users to connect its artificial intelligence chatbot with medical records and wellness apps. As we have been stating patients with diabetes collect mountains of data which often times is stored in different places. CGM data is one place, blood test results...
Digital Diabetes Where we stand today
Back during COVID digital health was all the rage. Many believed that thanks too COVID digital diabetes had come of age that finally at long last all the hype and expectations would become a reality. Sadly this was not the case for as we noted at the time once COVID went away people would go back to their old habits. Which is exactly what happened. However digital diabetes has not...
Beam me up Scottie
Released way back in 1966 it’s pretty amazing how many way cool whiz bang pieces of technology seen in Star Trek are now commonplace. We can now talk to computers; laptop computers are prevalent while AI is becoming commonplace. Based on the way things are going in the CGM space we could be on the cusp of another way cool whiz bang toy becoming commonplace. Is it possible that the...
What’s worth fighting for
When Abbott reported earnings last week CEO Robert Ford correctly noted on a global basis there are approximately 15 million patients using a CGM yet there are another 70 to 80 million who could be using a CGM. During the Dexcom investor day CEO Jake Leach noted that expanding reimbursement is an area of focus for the company. A sentiment shared by Mr. Ford. I mention this not to show...
ENOUGH IS ENOUGH
First off this is a post I am encouraging everyone to share. This hasn’t exactly been a good summer for the organizations who are supposed to represent the interests of people with diabetes. We have well documented the issues surrounding Breakthrough Type 1 and their T1D Fund. Meanwhile the ADA is in full blown scramble mode as their actions at their annual money grab won’t go away. Many had hoped that...